This study aimed to examine serum tenascin C (TNC) in different subsets of axial spondyloarthritis (axSpA) patients. Sixty-one patients fulfilling the Assessment of SpondyloArthritis international Society classification criteria for axSpA and 20 healthy subjects (HS) were included in study. Based on imaging, patients were classified as non-radiographic (n=16) and radiographic (n=45) axSpA. TNC serum levels were determined by ELISA. Disease-related factors including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and C-reactive protein (CRP) levels, were determined. TNC levels were elevated in axSpA patients [535.3 (457.7-677.2) ng/ml] compared to HS [432.1 (329.1-565.9) ng/ml, p=0.007]. Dividing axSpA into radiographic and non-radiographic subsets, the difference in TNC was observed between the radiographic subset and HS [535.3 (434.5-677.2) vs. 432.1 (329.1-565.9) ng/ml, p=0.022]. TNC levels did not correlate with disease activity measures (serum CRP or BASDAI). Nevertheless, the weak correlation of TNC levels with different disease stages (r=0.25, p=0.025) was found, with the highest levels in patients with syndesmophytes. TNC levels are elevated across various subsets of axSpA, and although not related to systemic disease activity, TNC levels might reflect chronic structural spinal changes in axSpA patients. However, its specific role in bone metabolism should be elucidated in further studies.

Institute of Rheumatology Prague Czech Republic

Zobrazit více v PubMed

AMONKAR SD, BERTENSHAW GP, CHEN TH, BERGSTROM KJ, ZHAO J, SESHAIAH P, YIP P, MANSFIELD BC. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One. 2009;4:e4599. doi: 10.1371/journal.pone.0004599. PubMed DOI PMC

BUBOVA K, FOREJTOVA S, ZEGZULKOVA K, GREGOVA M, HUSAKOVA M, FILKOVA M, HORINKOVA J, GATTEROVA J, TOMCIK M, SZCZUKOVA L, PAVELKA K, SENOLT L. Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open. 2019;9:e024713. doi: 10.1136/bmjopen-2018-024713. PubMed DOI PMC

DEODHAR SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med. 1989;56:126–130. doi: 10.3949/ccjm.56.2.126. PubMed DOI

DINCER U, CAKAR E, KIRALP MZ, DURSUN H. Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol. 2008;27:457–462. doi: 10.1007/s10067-007-0727-6. PubMed DOI

FOREJTOVA S, MANN H, STOLFA J, VEDRAL K, FENCLOVA I, NEMETHOVA D, PAVELKA K. Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol. 2008;27:1005–1013. doi: 10.1007/s10067-008-0845-9. PubMed DOI

GUPTA L, BHATTACHARYA S, AGGARWAL Tenascin-C, a biomarker of disease activity in early ankylosing spondylitis. Clin Rheumatol. 2018;37:1401–1405. doi: 10.1007/s10067-017-3938-5. PubMed DOI

HASEGAWA M, HIRATA H, SUDO A, KATO K, KAWASE D, KINOSHITA N, YOSHIDA T, UCHIDA A. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol. 2004;31:2021–2016. PubMed

HASEGAWA M, NAKOSHI Y, MURAKI M, SUDO A, KINOSHITA N, YOSHIDA T, UCHIDA A. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res. 2007;25:563–568. doi: 10.1002/jor.20366. PubMed DOI

JONES SD, CALIN A, STEINER A. An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach’s alpha scores. J Rheumatol. 1996;23:407. PubMed

MAKSYMOWYCH WP. An update on biomarker discovery and use in axial spondyloarthritis. Expert Rev Mol Diagn. 2017;17:965–974. doi: 10.1080/14737159.2017.1381562. PubMed DOI

MIDWOOD K, SACRE S, PICCININI AM, INGLIS J, TREBAUL A, CHAN E, DREXLER S, SOFAT N, KASHIWAGI M, OREND G, BRENNAN F, FOXWELL B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15:774–780. doi: 10.1038/nm.1987. PubMed DOI

MIDWOOD KS, CHIQUET M, TUCKER RP, OREND G. Tenascin-C at a glance. J Cell Sci. 2016;129:4321–4327. doi: 10.1242/jcs.190546. PubMed DOI

MIDWOOD KS, OREND G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009;3:287–310. doi: 10.1007/s12079-009-0075-1. PubMed DOI PMC

PAGE TH, CHARLES PJ, PICCININI AM, NICOLAIDOU V, TAYLOR PC, MIDWOOD KS. Raised circulating tenascin-C in rheumatoid arthritis. Arthritis Res Ther. 2012;14:R260. doi: 10.1186/ar4105. PubMed DOI PMC

PODDUBNYY DA, RUDWALEIT M, LISTING J, BRAUN J, SIEPER J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010;69:1338–1341. doi: 10.1136/ard.2009.120139. PubMed DOI

PRAJZLEROVA K, GROBELNA K, PAVELKA K, SENOLT L, FILKOVA M. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev. 2016;15:501–509. doi: 10.1016/j.autrev.2016.02.002. PubMed DOI

RUDWALEIT M, BRAUN J, SIEPER J ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL S. [ASAS classification criteria for axial spondyloarthritis] Z Rheumatol. 2009;68:591–593. doi: 10.1007/s00393-009-0510-y. PubMed DOI

RUHMANN M, PICCININI AM, KONG PL, MIDWOOD KS. Endogenous activation of adaptive immunity: tenascin-C drives interleukin-17 synthesis in murine arthritic joint disease. Arthritis Rheum. 2012;64:2179–2190. doi: 10.1002/art.34401. PubMed DOI

SATO A, AONUMA K, IMANAKA-YOSHIDA K, YOSHIDA T, ISOBE M, KAWASE D, KINOSHITA N, YAZAKI Y, HIROE M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2006;47:2319–2325. doi: 10.1016/j.jacc.2006.03.033. PubMed DOI

SHAO H, KIRKWOOD JM, WELLS A. Tenascin-C Signaling in melanoma. Cell Adh Migr. 2016;9:125–130. doi: 10.4161/19336918.2014.972781. PubMed DOI PMC

SHUKLA A, GAUR P, AGGARWAL A. Tenascin-C levels, a toll-like receptor 4 ligand, in enthesitis-related arthritis category of juvenile idiopathic arthritis: A cross-sectional and longitudinal study. J Rheumatol. 2015;42:891–896. doi: 10.3899/jrheum.141365. PubMed DOI

SIEPER J, PODDUBNYY D. Axial spondyloarthritis. Lancet. 2017;390:73–84. doi: 10.1016/S0140-6736(16)31591-4. PubMed DOI

SORENSEN J, HETLAND ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74:e12. doi: 10.1136/annrheumdis-2013-204867. PubMed DOI PMC

SPOORENBERG A, Van Der HEIJDE D, de KLERK E, DOUGADOS M, de VLAM K, MIELANTS H, Van Der TEMPEL H, Van Der LINDEN S. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999;26:980–984. PubMed

TANAKA H, EL-KAREF A, KAITO M, KINOSHITA N, FUJITA N, HORIIKE S, WATANABE S, YOSHIDA T, ADACHI Y. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int. 2006;26:311–318. doi: 10.1111/j.1478-3231.2005.01229.x. PubMed DOI

UDALOVA IA, RUHMANN M, THOMSON SJ, MIDWOOD KS. Expression and immune function of tenascin-C. Crit Rev Immunol. 2011;31:115–45. doi: 10.1615/CritRevImmunol.v31.i2.30. PubMed DOI

Van Der LINDEN S, VALKENBURG HA, CATS A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. doi: 10.1002/art.1780270401. PubMed DOI

ZÁVADA J, UHER M, SVOBODOVÁ R, OLEJÁROVÁ M, HUŠÁKOVÁ M, CIFERSKÁ H, HULEJOVÁ H, TOMČÍK M, ŠENOLT L, VENCOVSKÝ J. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate. Arthritis Res Ther. 2015;17:341. doi: 10.1186/s13075-015-0862-4. PubMed DOI PMC